David Carling

The EPO's Enlarged Board Of Appeal Has Changed The Interpretation Of Claims When Assessing Patentability

Does A Commercially Available Product Make Your Invention Unpatentable?

G1/24 - Referral To EPO's Enlarged Board Of Appeal On Claim Interpretation

EPO Board Of Appeal Gives Clarity On Interpreting G2/21 When Considering Post-filed Data For Inventive Step (T0116/18)

Description Amendments: Referral To EPO's Enlarged Board Of Appeal Now Imminent

Relief For US Applicants - EPO Takes A Pragmatic Decision On Priority

Proposed Changes To Pharmaceutical Regulatory Exclusivities In Europe

Frequently Asked Questions About The End Of The Ten-Day Rule

EPO Hints At Accepting The ‘PCT Joint Applicants' Approach For Priority

Plausible Or Not? EPO's Enlarged Board Of Appeal Leaves Us In The Dark On Post-filed Data And Inventive Step